In AML, the interactions between GA in NPM1, KMT2A, and menin protein have been linked to leukemogenesis and represent new potential targets for anti-tumor therapies, including menin inhibitors (such as revumenib, ziftomenib, bleximenib, and DSP-5336). This evidence concerns the gene NPM1 and acute myeloid leukemia.